Evaluation of the Contribution of Regular Cognitive Exercises to Treatment in Patients With Alzheimer's Disease
NCT ID: NCT03954613
Last Updated: 2022-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
198 participants
INTERVENTIONAL
2020-10-15
2024-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Donepezil and Memantine in Moderate to Severe Alzheimer's Disease
NCT00866060
Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
NCT02162251
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
NCT01539031
A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease
NCT00988598
Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease
NCT00555204
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Donepezil/Memantin Combination
Ebicomb
Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
Group B
Donepezil/Memantin Combination + Cognitive Exercises (BEYNEX Software)
Ebicomb
Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
Group C
Donepezil Mono
Ebicomb
Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
Group D
Donepezil Mono + Cognitive Exercises (BEYNEX Software)
Ebicomb
Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
Group E
Memantine Mono
Ebicomb
Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
Group F
Memantine Mono + Cognitive Exercises (BEYNEX Software)
Ebicomb
Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ebicomb
Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients without other neurodegenerative diseases and secondary dementia diagnoses,
* Patients with MOCA score of between 13-18,
* Patients with at least primary school graduation,
* Patients who have had no CNS disease including trauma in the last year,
* Patients without a diagnosis of psychiatric disease,
* Patients with a tablet or PC with an internet connection,
* Patients agreeing to perform BEYNEX daily activity at least 5 times per week,
* Patients signing informed consent form.
Exclusion Criteria
* Psychotic patients,
* Disabled patients with orthopedic dominant extremity,
* Patients with ICU follow-up due to trauma in the last 6 months,
* Patients with severe visual impairment or eye surgery,
* Patients who refuse to sign the informed consent form.
55 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Neutec Ar-Ge San ve Tic A.Ş
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Türker Şahiner, Prof Dr
Role: STUDY_CHAIR
Project Consultant
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maltepe University Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Nilgün Çınar
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NEU-05.18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.